Jacob Concurrent Financing
Pursuant to an engagement letter dated
Non-brokered Concurrent Financings
The Company may also elect to complete certain placements on a non-brokered basis (the "Non-brokered Concurrent Financing") and may pay a finder's fee on the Non-brokered Concurrent Financing upon regulatory approval.
Proceeds from the Jacob Concurrent Financing and the Non-brokered Concurrent Financing will be used for facilities development, marketing and working capital.
Following the closing of the Acquisition, the Company will, through its wholly-owned subsidiary OGI, be engaged in the licensed production of medical marihuana.
OGI is a licensed producer of medical marijuana. OGI carries out its principal activities producing and selling marijuana from its facilities in
Inform was incorporated under the Business Corporations Act (
Completion of the proposed transaction is subject to a number of conditions, including TSX-V acceptance and disinterested shareholder approval. The transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection with the transaction, any information released or received with respect to the RTO may not be accurate or complete and should not be relied upon. Trading in securities of
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FOR FURTHER INFORMATION PLEASE CONTACT:
Inform Exploration Corp. David DohertyPresident (604) 315-1237 Inform Exploration Corp. Aaron KeayDirector (604) 323-6911 OrganiGram Inc Denis ArsenaultCEO 1-855-961-9420 Source: Inform Exploration Corp.